FDA gives nod to BrainStorm for ALS trial after Phase III flop

[cafead]

via BrainStorm Cell Therapeutics will be initiating a Phase IIIb confirmatory trial of its lead candidate NurOwn after discussions with the US Food and Drug Administration (FDA) following a previous Phase III failure.

article source